Figure 4.

Toxicity of Intratracheal Administration of siRNA Dry Powder

(A) Body-weight fluctuation in mice with lung metastases treated with VEGF-siRNA dry powder, non-target siRNA dry powder, or PBS (mean ± SE). There was no significant difference in body weight between groups during the time course (n = 5–6/group). (B–E) Representative histological appearance of H&E-stained lung sections from mice treated with VEGF-siRNA (B), non-target siRNA (C), PBS (D), and bleomycin (E). The bleomycin group (intratracheal injection of 2.5 mg/kg body weight) served as a positive control. Scale bar, 100 μm.